ASCO GI 2024 | cfDNA assessment of esophagogastric cancer using MSK-ACCESS

Samuel Louis Cytryn, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents research on the use of circulating free DNA (cfDNA) analysis in esophagogastric (EG) cancer. The study involved 98 patients, with 80% having cfDNA obtained prior to treatment and 21% at the time of progression. Comparisons between cfDNA and tumor next-generation sequencing (NGS) showed a similar molecular profile, though cfDNA was more frequent in metastatic cases. Notably, baseline detection of ctDNA (circulating tumor DNA) suggested poor prognosis and undetectable ctDNA correlated with improved progression-free survival and overall survival in untreated metastatic cases. The study underscores cfDNA’s potential as a complementary tool for molecular characterization and prognostication in EG cancer. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.